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Developing multiple soft tissue sarcomas (STSs) is a rare process, sparsely reported in the literature to date. Little is known about
the pattern of disease development or outcomes in these patients. Patients were identiﬁed from three tertiary orthopaedic
oncology centres in Canada and the UK. Patients who developed multiple extremity STSs were collated retrospectively from
prospective oncology databases. A literature review using MEDLINE was also performed. Six patients were identiﬁed in the case
series from these three institutions, and ﬁve studies were identiﬁed from the literature review. Overall, 17 patients were identiﬁed
with a median age of 51 years (range: 19 to 77). +e prevalence of this manifestation in STS patients is 1 in 1225. +e median
disease-free interval between diagnoses was 2.3 years (range: 0 to 19 years). Most patients developed the secondary STS in
a metachronous pattern, the remaining, synchronously. +e median survival after the ﬁrst sarcoma was 6 years, and it was 1.6
years after the second sarcoma. +e 5-year overall survival rate was 83.3% and 50% following the ﬁrst and second STS diagnoses,
respectively. A diagnosis of two STSs does not confer a worse prognosis than the diagnosis of a single STS. Developing a second
STS is a rare event with no identiﬁable histological pattern of occurrence. Presentation in a metachronous pattern is more
common. A high degree of vigilance is required in patients with a previous STS both to detect both local recurrence and to identify
new masses remote from the previous STS site. Acquiring an early histological diagnosis should be attempted.
1. Introduction
Soft tissue sarcoma (STS) is a general term assigned to
a group of rare malignant tumours arising from a mesen-
chymal stem cell. +e term “sarcoma” encompasses ap-
proximately 100 diﬀerent histological subtypes of tumour as
per the latest World Health Organization Classiﬁcation of
Tumours of Soft Tissue and Bone (4th edition) [1]. STS
accounts for less than 1% of all malignant neoplasms in
adults and around 4–8% in children [2]. Prognosis for
sarcomas has improved, on average the 5-year overall
survival rate being around 60% [3]. However, this ﬁgure
varies widely depending on the tumour grade, size, stage at
diagnosis, depth, location, and histological subtype [4]. +e
most commonly used staging system for STS (the American
Joint Committee on Cancer [5]) uses the ﬁrst three listed
prognostic factors when calculating the stage of a sarcoma.
Commonly, the primary complaint of a patient pre-
senting with a suspected soft tissue sarcoma is the presence
of an enlarging, painless mass. Detailed evaluation of the
mass and its association with surrounding structures is
crucial [6]. Certain types of STSs (synovial sarcoma,
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epithelioid sarcoma, clear-cell sarcoma, rhabdomyosar-
coma, and angiosarcoma) have a tendency to spread via the
lymphatic system, thereby warranting palpation of local
lymphatics for other masses [7]. However, it is not currently
considered routine practice to screen for a second primary
soft tissue mass on an initial evaluation for sarcoma.
Although uncommon, patients with STS have an in-
creased risk of developing a second primary neoplasm
(carcinoma), even when excluding known syndromic as-
sociations such as Li–Fraumeni syndrome and neuroﬁ-
bromatosis [8, 9]. Outside of these syndromes, there have
been very few reports on patients developing multiple STSs.
Furthermore, there are no reports on how the development
of multiple STSs correlates with patient survival. +is study
aims to elucidate the impact of a diagnosis of multiple STSs
on survival and whether there are any associated chrono-
logical or histological disease patterns.
2. Methods
2.1. Patient Identiﬁcation. Two tertiary sarcoma centres in
Canada and one in the United Kingdom collaborated in this
study. A retrospective review from 1997 to July 2017 was
conducted using the prospectively collated oncology data-
bases at each centre. Electronic notes were searched using
a combination of the following terms: “sarcoma,” “multiple,”
“new,” “diﬀerent,” “synchronous,” and “metachronous.” A
list of patients was generated when the database notes in-
dicated the possibility of a second primary soft tissue sar-
coma. Patients with two or more histologically conﬁrmed
extremity STSs were manually identiﬁed. Clinical in-
formation including the patient demographics, pathologic
diagnosis, tumour site, operation, and survival outcomes
were gathered from clinical notes. Diagnoses were made by
specialized musculoskeletal pathologists at the three centres.
No minimum follow-up criteria were assigned in order to
maximize inclusion.
In most cases, access to both STS specimens was
available to allow direct comparison for accurate histological
diagnosis and to distinguish this from a distant soft tissue
metastasis of the original primary sarcoma or a radiation-
induced sarcoma. Cahan’s criteria were used to discern
a second primary sarcoma from an iatrogenic sarcoma
secondary to radiation, which are a latency period of at least
2 years, the tumour must arise in the direct region of
previous radiation, and the sarcoma must be histologically
diﬀerent from the previously radiated lesion [10].
2.2. Literature Review. A search was conducted using the
MEDLINE OVID interface from 1946 to July 2017. +e
search strategy used was [Sarcoma OR ST neoplasm] AND
[synchronous OR metachronous]. Inclusion criteria in-
cluded English, human studies with one or more of the
subjects with multiple sarcomas. +is yielded 157 results, of
which ﬁve papers were identiﬁed that met the inclusion
criteria (Figure 1). Manual searching through reference lists
was also conducted.
Patients identiﬁed in our case series and in the literature
review with desmoid tumours, Kaposi sarcoma, and gas-
trointestinal stromal tumours (GISTs) were excluded from
the study due to their unique disease pattern which diﬀers
from that of other STSs.
3. Results
3.1. Case Series. Six patients were identiﬁed to meet the
study inclusion criteria after detailed interrogation of the
databases from the three tertiary orthopaedic oncology
centres. Amongst all patients with STS at these centres
(n � 7351), this amounted to a prevalence of 0.08%. +e
median age of the patients in our series was 54.5 years
(range: 28 to 67). Five (83.3%) of the patients were male, and
the other was female. +e median interval between the
diagnosis of the primary and secondary sarcomas was 2.7
years (range: 0.1 to 4.6 years).
Four (66.7%) patients developed sarcomas in a meta-
chronous pattern. +e diagnosis interval for the remaining
two patients was 1 and 5 months. Although both primary
tumours were not diagnosed at the same time, the interval is
short enough to be considered a synchronous pattern. Four
patients developed their second STS on the ipsilateral side to
the ﬁrst, three of which occurred in diﬀerent areas of the
same limb, while the fourth patient’s ﬁrst STS occurred in
the hand followed by one in the lower limb. Liposarcoma
was the most common diagnosis, followed by un-
diﬀerentiated pleomorphic sarcoma (Table 1).
+e median time from ﬁrst sarcoma diagnosis to last
follow-up was 7.7 years (range: 0.8 to 12.9). Five (83.3%)
patients were alive with no evidence of disease at last follow-
Search results aer duplicates removed: 157 
Articles included: 5
Excluded due to not including a case of
multiple STSs: 102 
Excluded due to not being related to so tissue
sarcoma: 37
Excluded due to language: 13 
Figure 1: Results of the literature search.
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up. One patient developed a local recurrence 33months after
resection of their second sarcoma; however, this was
resected, and the patient remained free of disease before
dying 7 years later with no evidence of sarcoma recurrence.
Two patients developed metastasis amenable to complete
metastasectomy at 2 and 60months after the ﬁrst and second
STS excision, respectively. Following metastasectomy, these
patients had no evidence of disease at 10.1 and 3.2 years of
follow-up.
All patients were managed under the care of a sarcoma
multidisciplinary team (MDT), with treatment following
international guidelines active at the time. One patient was
treated with radiotherapy for both sarcomas, while ﬁve
patients received radiation for only one of their two sar-
comas. Of the patients who underwent radiotherapy for only
one sarcoma, two received it for the ﬁrst sarcoma and three
for the second sarcoma. No patients received adjuvant
chemotherapy treatment.
Postoperative surveillance comprised clinical examina-
tion for evidence of local and regional recurrence with
subsequent magnetic resonance imaging (MRI) based on
concerning clinical ﬁndings and chest radiography with
subsequent computerized tomography (CT) to conﬁrm
metastasis based on abnormal radiographs. Follow-up oc-
curred at 3-month intervals for the ﬁrst 2 years, 6-month
intervals until 5 years, and annually until 10 years following
resection as per international guidelines [11].
3.2. Literature Review. Five patient series were identiﬁed
that included patients with multiple diﬀerent histologically
conﬁrmed STSs [8, 9, 12–14]. Two of the articles were case
reports, and three were case series. From these ﬁve articles,
17 additional patients were identiﬁed. However, seven pa-
tients did not meet our inclusion criteria and were therefore
excluded. Six patients were excluded from the study by
Grobmyer et al. since the diagnoses include GIST or ma-
lignant mixed Mullerian tumour. One patient was excluded
from the study byMerimsky et al. due to the possibility of the
second sarcoma being radiation-induced [8, 9].
3.3. Combination of Case Series and Literature Review
Cases. Combining data from our current case series and
patients selected from the other ﬁve series equated to a total
of 17 patients with a median age of 51 years (range: 19 to 77)
including 9 males and 6 females (two patients’ sex were not
reported). +e median interval between the ﬁrst and second
STS diagnoses was 2.3 years (range: 0 to 19). +is included 6
(35.3%) synchronous manifestations of multiple sarcomas
and 11 patients (64.7%) that developed distinct tumours in
a metachronous pattern. +e most common diagnosis was
undiﬀerentiated pleomorphic sarcoma (n � 8, 23.5%) fol-
lowed by liposarcoma (n � 6, 17.6%) and leiomyosarcoma
(n � 5, 14.7%). From available data, 7 (53.8%) patients’
second tumours arose on the contralateral side and 6 (46.2%)
on the ipsilateral side. Overall, tumours presented as high
grade (grade 3) in 57.1% of cases, intermediate grade (grade
2) in 28.6% of cases, and low grade (grade 1) in 14.3% of
cases (Tables 1 and 2).
+e median time from ﬁrst tumour diagnosis to death or
last follow-up was 6 years (range: 0.2 to 26). +e 5-year
overall survival rate was 83.3%. Median survival time from
the second sarcoma diagnosis was 1.6 years (range: 0 to 19)
with a 5-year disease-free survival rate of 50%. Overall, six
patients were deceased, and 11 were alive with no evidence of
disease at last follow-up.
One series which included four patients did not report
information on adjuvant therapy [8]. From the available
information pertaining to the other 14 patients, adjuvant or
neoadjuvant radiotherapy was utilized in 12 patients
(85.7%). +ree patients were treated with chemotherapy.
4. Discussion
A case series of 6 patients and literature review of 11 patients
were conducted on multiple primary STSs occurring in
individual patients. +e aim of the study was to determine
the impact developing a second primary STS had on overall
survival and whether there are any predictable histological
or chronological patterns to disease presentation. We hoped
to better enable clinicians to provide a prognosis when faced
with these patients as well as to advise on routine STS follow-
up. +e prognosis in these patients was found to be poor
relative to patients with one STS diagnosis, and no pre-
dictable patterns of disease presentation were identiﬁed.
+ere are many possible explanations for the develop-
ment of multiple sarcomas in a single patient. One possi-
bility is that these patients may have a genetic predisposition
to malignant mesenchymal disease that is currently not
described. Alternatively, general risk factors for malignancy
may have been the underlying cause such as immuno-
compromise or exposure to carcinogens, either environ-
mental or iatrogenic.+ese factors have been associated with
the formation of cancers [15–17], although uncommonly
associated with STS. Many other possibilities can be hy-
pothesized but are diﬃcult to identify due to the rarity of the
disease.
+e median survival time from the ﬁrst STS diagnosis
was 6 years; however, it was only 1.6 years after the second
STS diagnosis. +e 5-year disease-free survival was 83.3%
and 50%, after the ﬁrst and second STS diagnoses, re-
spectively. +e American Cancer Society reported the mean
5-year survival rate of STS as 64% in 2017 [3]. In our review,
the survival rate following the ﬁrst STS diagnosis compares
favourably. However, the 5-year survivorship of 50% fol-
lowing the second STS diagnosis is lower relative to the
reported mean. +is may be due to the morbidity associated
with having a second tumour or the complications associ-
ated with additional treatment. However, these survival rates
may have been negatively aﬀected by a number of con-
founding factors, such as the short length of follow-up, the
second STS diagnosis representing soft tissue metastases of
the primary STS rather than a new primary, or because
patients in one of the identiﬁed studies generally doing
poorly [9]. Isolating patients from our case series, there was
no evidence of multiple STSs conferring a poorer prognosis,
as ﬁve of six patients had no evidence of disease at last
follow-up with the other patient dying of unrelated causes.
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Using available data, it is diﬃcult to determine whether the
length of the latent period between the STS diagnoses
correlates with survival. However, we could anticipate an
improved prognosis following the second STS if this tumour
arises whilst patients are still being followed-up at a sarcoma
centre for their ﬁrst STS.
+e prevalence of a patient with one STS developing
a second STS is low, 0.082% or 1 in 1225. Grobmyer et al.
were also able to determine the incidence of developing two
STSs. +ey reported that, in a patient previously diagnosed
with STS, the incidence of a second primary sarcoma was 1
per 2500 population, or 12.5 times greater than the standard
incidence of STS [8]. +erefore, although still a relatively
unusual event, the higher incidence in primary sarcoma
patients needs to be kept in mind when following up these
patients [18, 19].
No identiﬁable patterns were identiﬁed in terms of
distinct STS subtypes presenting together in the same pa-
tient. +e type of sarcoma that arises secondarily appears to
be random, independent of the ﬁrst sarcoma diagnosis. +e
time used to deﬁne synchronous development was 6 months
or less between diagnoses. +is cutoﬀ time was chosen as it
would be too narrow of an interval to develop two individual
primaries meaning that the second tumour likely went
unrecognized previously.+emedian time between sarcoma
diagnoses was 2.3 years. Approximately one-third of patients
developed the second sarcoma in a synchronous pattern,
while in two-thirds, the second sarcoma developed meta-
chronously. +erefore, more attention should be paid to
identifying a second STS in patients during the postoperative
follow-up period. Over recent years, there has been an in-
crease in the use of whole-body staging studies, such as
ﬂuorodeoxyglucose positron emission tomography (FDG-
PET) or whole body MRI. +is may lead to an earlier de-
tection of a second primary tumour in those patients who are
undergoing staging at the initial diagnosis but also have
a synchronous second primary STS. However, the cost and
availability associated with the routine use of these tests need
to be considered in light of the rarity of a diagnosis of
a second soft tissue sarcoma.
+e occurrence of a second STS in the same patient is
very rare, and therefore, no change to the management of
new patients or patient follow-up is recommended. During
follow-up visits for a primary STS, a short screening phrase
such as “Have you noticed any new lumps or bumps?” is
recommended to raise attention to any newly developing
masses. Any second mass a patient develops should not be
presumed to be the same disease, and new histological
diagnosis should be made. +erefore, we recommend
reimaging, restaging, and a biopsy to help diagnose new
disease, including radiation-induced tumours, from re-
currence or metastasis [18]. In fact, new disease should
always be suspected. Merimsky et al. noticed that the risk of
developing a secondary neoplasm in patients with STS is
signiﬁcantly greater than that in the general population,
7.5% compared to 1% [9]. +erefore, thorough screening
for new STSs or other neoplasms should be considered for
patients with new symptoms at follow-up since they are at
increased risk.
Unfortunately, several limitations to interpreting these
ﬁgures exist including the short follow-up period of many
patients. Only 12 of the 17 patients had follow-up to ﬁve
years after diagnosis of their ﬁrst sarcoma. As well, all pa-
tients from one series had very short survival after the
second STS diagnosis, which may have skewed the results
[9]. Another limitation includes the limited number of
patients, hand-selected from observational data potentially
introducing selection bias. Although all histologies were
reviewed by a specialist musculoskeletal pathologist, they
were not reviewed by the same pathologist, which may have
slightly altered certain diagnoses. +ere were six cases
identiﬁed in the literature review with the same histological
diagnosis for the ﬁrst and second sarcomas. Although re-
ported as diﬀerent sarcomas, we are uncertain as to whether
these cases truly represent multiple distinct STSs or soft
tissue metastases of previous sarcomas. Genetic testing was
not routinely conducted; however, this could be considered
for future studies. Although these limitations are recognized,
this study helps to clarify this rare manifestation.
Further research is recommended as current available
evidence is limited. Larger series of other orthopaedic on-
cology centres’ experience and more case reports are en-
couraged to increase the amount of described information.
+is will hopefully help to uncover any patterns of disease
occurrence which may lead to identifying risk factors or
certain genetic predispositions.
5. Conclusion
In conclusion, this study aimed to help deﬁne the pattern of
disease and outcomes in patients with nonsyndromic, non-
radiation-induced multiple extremity STSs. +e incidence of
this scenario is very low, and more reports are encour-
aged. +is study was unable to deﬁnitively demonstrate that
patient prognosis with multiple STSs is poor relative to those
diagnosed with a single sarcoma. A high index of suspicion
should be maintained to detect a second STS in patients with
a current or previous primary STS as they are at an increased
risk compared to the general population. Our results dem-
onstrate that majority of patients with multiple STSs present
in a metachronous pattern of disease and require routine
long-term screening. Management of the second sarcoma
should continue in line with internationally recognized
guidelines. +e recommendations for practice include thor-
ough screening for any new symptoms as well as ensuring
a second histological diagnosis is made in the setting of a
new mass.
Conflicts of Interest
+e authors declare that they have no conﬂicts of interest.
References
[1] V. Y. Jo and C. D. Fletcher, “WHO classiﬁcation of soft tissue
tumours: an update based on the 2013 (4th) edition,” Pa-
thology, vol. 46, no. 2, pp. 95–104, 2014.
[2] F. Ducimetiere, A. Lurkin, D. Ranche`re-Vince et al., “In-
cidence of sarcoma histotypes and molecular subtypes in
6 Sarcoma
a prospective epidemiological study with central pathology
review and molecular testing,” PloS One, vol. 6, no. 8, article
e20294, 2011.
[3] American Cancer Society, Cancer Facts & Figures, American
Cancer Society, Atlanta, Georgia, 2017.
[4] R. Grimer, I. Judson, D. Peake, and B. Seddon, “Guidelines for
the management of soft tissue sarcomas,” Sarcoma, vol. 2010,
Article ID 506182, 15 pages, 2010.
[5] J. S. Wunder, J. H. Healey, A. M. Davis, andM. F. Brennan, “A
comparison of staging systems for localized extremity soft
tissue sarcoma,” Cancer, vol. 88, no. 12, pp. 2721–2730, 2000.
[6] E. M. Ramu, M. T. Houdek, C. E. Isaac, C. I. Dickie,
P. C. Ferguson, and J. S. Wunder, “Management of soft-tissue
sarcomas; treatment strategies, staging, and outcomes,”
SICOT Journal, vol. 3, no. 20, 2017.
[7] S. Riad, A. M. Griﬃn, B. Liberman et al., “Lymph node
metastasis in soft tissue sarcoma in an extremity,” Clinical
Orthopaedics and Related Research, vol. 426, pp. 129–134,
2004.
[8] S. R. Grobmyer, N. Luther, C. Antonescu, S. Singer, and
M. Brennan, “Multiple primary soft tissue sarcomas,” Cancer,
vol. 101, no. 11, pp. 2633–2635, 2004.
[9] O. Merimsky, Y. Kollender, J. Issakov et al., “Multiple primary
malignancies in association with soft tissue sarcomas,”
Cancer, vol. 91, no. 7, pp. 1363–1371, 2001.
[10] W. G. Cahan, H. Q. Woodard, N. L. Higinbotham,
F. W. Stewart, and B. L. Coley, “Sarcoma arising in irradiated
bone; report of 11 cases,” Cancer, vol. 1, no. 1, pp. 3–29, 1948.
[11] +e ESMO/European Sarcoma Network Working Group,
“Soft tissue and visceral sarcomas: ESMO Clinical Practice
Guidelines,” Annals of Oncology, vol. 25, no. 3, pp. iii102–
iii112, 2014.
[12] R. Schiﬀman, “Epithelioid sarcoma and synovial sarcoma in
the same knee,” Cancer, vol. 45, no. 1, pp. 158–166, 2001.
[13] A. Daigeler, M. Lehnhardt, A. Sebastian et al., “Metachronous
bilateral soft tissue sarcoma of the extremities,” Langenbeck’s
Archives of Surgery, vol. 393, no. 2, pp. 207–212, 2008.
[14] D. Scepanovic, A. Masarykova, M. Pobijakova, A. Hanicova,
and M. Fekete, “Multiple metachronous malignant ﬁbrous
histiocytomas of the upper limbs–a case report,” Klinicka
Onkologie, vol. 27, no. 6, pp. 438–441, 2014.
[15] E. S. Gilbert, “Ionizing radiation and cancer risks: what have
we learned from epidemiology?,” International Journal of
Radiation Biology, vol. 85, no. 6, pp. 467–482, 2009.
[16] A. E. Grulich, M. T. van Leeuwen, M. O. Falster, and
C. M. Vajdic, “Incidence of cancers in people with HIV/AIDS
comparedwith immunosuppressed transplant recipients: ameta-
analysis,” 8e Lancet, vol. 370, no. 9581, pp. 59–67, 2007.
[17] S. R. Patel, “Radiation-induced sarcoma,” Current Treatment
Options in Oncology, vol. 1, no. 3, pp. 258–261, 2000.
[18] P.G. Casali, J. Y. Blay, andESMO/CONTICANET/EUROBONET
Consensus Panel of experts, “Soft tissue sarcomas: ESMO
Clinical Practice Guidelines for diagnosis, treatment and follow-
up,” Annals of Oncology, vol. 21, no. 5, pp. 198–203, 2010.
[19] M. A. Clark, C. Fisher, I. Judson, and J. M.+omas, “Soft-tissue
sarcomas in adults,”New England Journal of Medicine, vol. 353,
no. 7, pp. 701–711, 2005.
Sarcoma 7
Stem Cells 
International
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
MEDIATORS
INFLAMMATION
of
Endocrinology
International Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Disease Markers
Hindawi
www.hindawi.com Volume 2018
BioMed 
Research International
Oncology
Journal of
Hindawi
www.hindawi.com Volume 2013
Hindawi
www.hindawi.com Volume 2018
Oxidative Medicine and 
Cellular Longevity
Hindawi
www.hindawi.com Volume 2018
PPAR Research
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013www.hindawi.com
The Scientific 
World Journal
8
Immunology Research
Hindawi
www.hindawi.com Volume 2018
Journal of
Obesity
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
 Computational and  
Mathematical Methods 
in Medicine
Hindawi
www.hindawi.com Volume 2018
Behavioural 
Neurology
Ophthalmology
Journal of
Hindawi
www.hindawi.com Volume 2018
Diabetes Research
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Research and Treatment
AIDS
Hindawi
www.hindawi.com Volume 2018
Gastroenterology 
Research and Practice
Hindawi
www.hindawi.com Volume 2018
Parkinson’s 
Disease
Evidence-Based 
Complementary and
Alternative Medicine
Volume 2018
Hindawi
www.hindawi.com
Submit your manuscripts at
www.hindawi.com
